Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €29.00 EUR
Change Today -0.85 / -2.85%
Volume 39.7K
As of 11:35 AM 03/6/15 All times are local (Market data is delayed by at least 15 minutes).

erytech pharma (ERYP) Snapshot

Open
€30.00
Previous Close
€29.85
Day High
€30.15
Day Low
€29.00
52 Week High
10/1/14 - €34.97
52 Week Low
08/8/14 - €12.12
Market Cap
199.6M
Average Volume 10 Days
43.0K
EPS TTM
€-1.44
Shares Outstanding
6.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ERYTECH PHARMA (ERYP)

Related News

No related news articles were found.

erytech pharma (ERYP) Related Businessweek News

No Related Businessweek News Found

erytech pharma (ERYP) Details

ERYTECH Pharma, société anonyme develops cancer therapies. The company’s proprietary technology is based on encapsulation of therapeutic molecules into red blood cells. It is developing ERY-ASP that consists of red blood cell-encapsulated L-asparaginase, which destroys asparagine inside the red blood cell, preventing allergic reactions and reducing other adverse events. The company is developing ERY-ASP for the treatment of acute lymphoblastic leukaemia, acute myeloid leukaemia, and solid tumours. The company was founded in 2004 and is headquartered in Lyon, France.

37 Employees
Last Reported Date: 08/29/14
Founded in 2004

erytech pharma (ERYP) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: €164.7K
Co-Founder, Chief Scientific Officer, Deputy ...
Total Annual Compensation: €240.0K
Director of Pharmaceutical Operations and Dep...
Total Annual Compensation: €60.3K
Consultant
Total Annual Compensation: €240.8K
Compensation as of Fiscal Year 2013.

erytech pharma (ERYP) Key Developments

Erytech Pharma Société Anonyme Presents at 3rd Annual SACHS Cancer Bio Partnering and Investment Forum, Feb-23-2015

Erytech Pharma Société Anonyme Presents at 3rd Annual SACHS Cancer Bio Partnering and Investment Forum, Feb-23-2015. Venue: The New York Academy of Sciences, 7 World Trade Center, 250 Greenwich St, 40th Floor (D Elevator Bank), New York, NY10007, United States. Presentation Date & Speakers: Feb-23-2015, Gil Beyen, Chairman and Chief Executive Officer.

Erytech Pharma Société Anonyme Presents at 17th Annual BIO CEO & Investor Conference, Feb-09-2015 04:30 PM

Erytech Pharma Société Anonyme Presents at 17th Annual BIO CEO & Investor Conference, Feb-09-2015 04:30 PM. Venue: The Waldorf Astoria, New York, New York, United States.

Erytech Pharma Société Anonyme to Report Fiscal Year 2014 Sales/Trading Statement Results on Feb 10, 2015

Erytech Pharma Société Anonyme announced that they will report fiscal year 2014 sales/trading statement results After-Market on Feb 10, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ERYP:FP €29.00 EUR -0.85

ERYP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ERYP.
View Industry Companies
 

Industry Analysis

ERYP

Industry Average

Valuation ERYP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 88.9x
Price/Book 12.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 100.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ERYTECH PHARMA, please visit erytech.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.